SBIR/STTR Research Award
Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure
Award amount
$225,000Program and phase
STTR · Phase IAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ADGERO BIOPHARMACEUTICALS HOLDINGS INC
- Proposal award date
- 2020-07-17
- Contract end date
- 2021-06-30
- UEI
- DKFQRJXK7SD3
- Solicitation number
- PA18-575
- Topic code
- NHLBI
Research abstract
Project Summary - Photodynamic Therapy to Prevent Arterio-Venous Fistula Maturation
Failure: An Unmet Clinical Need
Establishing and maintaining arteriovenous (AV) access sites is critical for patients on
hemodialysis. The most preferred AV access is the forearm fistula which is now used for the
majority of hemodialysis patients. However, a common problem with AV fistulas is primary
maturation failure, i.e. following surgical placement, their fistulas do not become viable for dialysis
without additional percutaneous or surgical interventions and some never become viable. This
failure can lead to increased morbidity from prolonged use of central venous catheters and results
in a large financial cost to the health care system. This is particularly frustrating because it is well
established that a mature fistula provides the hemodialysis patient with the most effective means
of AV access. While the exact mechanisms of maturation failure are not fully understood, it is
generally accepted that post-surgical neointimal hyperplasia and inadequate venous remodeling
play key roles and preventing either of these processes should substantially improve AV fistula
outcomes.
This project will investigate the potential for a particular form of photodynamic therapy to improve
fistula maturation rates. Preliminary studies in related cardiovascular models indicate this therapy
could substantially impact the main failure mechanisms involved in fistula maturation failure.
From a commercialization perspective, this therapy also has the advantage that is already under
late stage development in an unrelated disease indication, thus the typical drug development risks
are substantially reduced. The project will be a joint effort between a commercial entity whose
staff has extensive experience in vascular photodynamic therapy and a research partner who is
a leader in AV access preclinical and clinical research.
This Phase I project will focus on validating this therapy in an established preclinical model of AV
fistula maturation failure. If this project is successful, it is envisioned that this technology should
be suitable for initial clinical feasibility studies within the near term.Project Narrative - Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation
Failure: An Unmet Clinical Need
This project’s aims to develop a therapy to substantially reduce the risk of arteriovenouos (AV)
fistula failure in hemodialysis patients. Currently patients receiving such fistulas have primary
failure rates as high as 60% resulting in the need for subsequent surgeries or percutaneous
procedures that result in high added costs and extended periods of central catheter use which
often results in associated morbidities. We envision that ultimate success in this effort could
substantially reduce the costs and morbidities associated with AV access maintenance, an area
where current medical expenditure in the US is estimated to be on the order of $5 billion.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications